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Background: Although transfusion is a paramount life-saving therapy, there are multiple 
potential significant risks. Therefore, all adverse transfusion reaction (ATR) episodes re-
quire close monitoring. Using the computerized reporting system, we assessed the fre-
quency and pattern of non-infectious ATRs.
Methods: We analyzed two-year transfusion data from electronic medical records retro-
spectively. From March 2013 to February 2015, 364,569 units of blood were transfused. 
Of them, 334,582 (91.8%) records were identified from electronic nursing records. For 
the confirmation of ATRs by blood bank physicians, patients’ electronic medical records 
were further evaluated.
Results: According to the nursing records, the frequency of all possible transfusion-related 
events was 3.1%. After the blood bank physicians’ review, the frequency was found to be 
1.2%. The overall frequency of febrile non-hemolytic transfusion reactions (FNHTRs) to 
red blood cells (RBCs), platelet (PLT) components, and fresh frozen plasmas (FFPs) were 
0.9%, 0.3%, and 0.2%, respectively, and allergic reactions represented 0.3% (RBCs), 
0.9% (PLTs), and 0.9% (FFPs), respectively. The pre-storage leukocyte reduction signifi-
cantly decreased the frequency of FNHTRs during the transfusion of RBCs (P <0.01) or 
PLTs (P≒0.01).
Conclusions: The frequency of FNHTRs, allergic reactions, and “no reactions” were 
22.0%, 17.0%, and 60.7%, respectively. Leukocyte-reduction was associated with a lower 
rate of FNHTRs, but not with that of allergic reactions. The development of an effective 
electronic reporting system of ATRs is important in quantifying transfusion-related adverse 
events. This type of reporting system can also accurately identify the underlying problems 
and risk factors to further the quality of transfusion care for patients.
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INTRODUCTION
Blood and blood components are essential for many patients. 
However, some patients may be exposed to risk factors during 
the administration of allogeneic blood or blood components [1]. 
Adverse transfusion reactions (ATRs) can be infectious or non-
infectious. The risk of infectious ATRs has dramatically de-
creased by approximately 10,000-fold because of strict donor 
screening and the development of techniques such as nucleic 
acid amplification tests and chemiluminescent immunoassays 
for detecting infectious agents [2]. Besides, improved blood 
management systems have contributed to better quality of blood 
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and blood components, and have decreased the risk associated 
with the transfusion procedure. The incidence of non-infectious 
ATRs has also decreased, but it still remains high [3]. Although a 
majority of these reactions, such as febrile non-hemolytic trans-
fusion reactions (FNHTRs) and allergic reactions are short-term 
and reversible, a few of these can cause significant morbidities, 
such as transfusion-related acute lung injury (TRALI) and trans-
fusion-associated dyspnea (TAD), and mortality [4]. Cytokines 
and antibodies that accumulate in stored allogeneic blood and 
blood components are responsible for these reactions [3].
Many patients experience physical changes during transfu-
sion. Most of these changes do not meet the criteria for ATRs or 
can be attributed to patients’ underlying diseases and comor-
bidities [1]. The overall incidence of ATRs is about 0.5-3% [5], 
and types of ATRs vary according to pathophysiology, symp-
toms, and severity. The diagnosis of ATR may be difficult be-
cause of overlapping conditions in the patient and the underly-
ing disease [1]. Therefore, a comprehensive approach is re-
quired on part of the attending physician, such that ATR can be 
assumed once other differential diagnoses have been ruled out 
[1, 6].
Until 2012, in our hospital, ATRs were directly reported by the 
clinicians in the transfusion wards, based on their clinical judg-
ment. With no ATR report submitted to the blood bank, it was 
assumed that no ATR had occurred during the transfusion epi-
sode. However, this reporting process under-reported the inci-
dence of ATRs, thus undermining the risk associated with the 
transfusion procedure. Notably, in order to comply with the re-
quirements of the Joint Commission International (JCI) and the 
Korea Hemovigilance System (http://www.kohevis.or.kr) on 
blood transfusion monitoring, our hospital introduced data-
driven improvements in the ATR reporting process. 
In this study, we measured the frequency and pattern of non-
infectious ATRs at a tertiary care hospital using the newly devel-
oped online transfusion reaction reporting system and assessed 
the possible factors affecting these reactions with an aim to 
contribute to improved patient safety during transfusion.
METHODS
1. Study design
Data for this study were collected from the electronic medical 
records (EMR) of Yonsei University Health System-affiliated Sev-
erance Hospital, a 2,089-bed tertiary care hospital in Seoul, Ko-
rea.
This study involved a retrospective observational analysis of 
Table 1. Definition of different types of ATRs in accordance with the AABB [6] and CDC [7] criteria
Type Etiology Clinical presentation
Febrile non-hemolytic
   transfusion reaction (FNHTR)
Cytokines in donor platelets or antibodies to donor leukocytes Fever (≥1°C increase and ≥38.0°C body temperature) within the    
   first four hours of transfusion and/or chills/rigors without any 
   evidence of infection or other conditions causing fever
Allergic reaction Antibodies to donor plasma proteins Urticaria, pruritus, rash, edema, or flushing within the first four hours 
   of transfusion and/or itching sensation without any evidence of 
   other conditions causing allergic reactions
Transfusion-associated
   dyspnea (TAD)
Acute respiratory distress within the first 24 hr of transfusion without 
   any evidence of other conditions causing similar symptoms, and 
   when TACO and TRALI have been ruled out
Transfusion-associated
   circulatory overload (TACO)
Volume overload Gallop, jugular venous distension, cough, or dyspnea within the first 
   six hours of transfusion with elevated BNP and CVP with radiologic 
   evidence of pulmonary edema without any evidence of other 
   conditions causing circulatory overload
Transfusion-related
   acute lung injury (TRALI)
Leukocyte antibodies in donor or recipient Respiratory failure, hypotension, fever within the first six hours of 
   transfusion with the evidence of hypoxemia (PaO2/FiO2 ≤300 mm Hg 
   and SaO2 <90% in room air) with radiologic evidence of pulmonary 
   edema without evidence of circulatory overload (PCWP ≥18 mm Hg) 
   and other conditions causing acute lung injury
Hypotensive transfusion
   reaction (HTR)
Hypotension (≥30 mm Hg drop and ≤80 mm Hg systolic blood 
   pressure) within the first four hours of transfusion without any 
   evidence of other conditions causing hypotension
Abbreviations: AABB, American Association of Blood Banks; CDC, Centers for Disease Control and Prevention; ATR, adverse transfusion reaction; BNP, 
brain natriuretic peptide; CVP, central venous pressure; PCWP, pulmonary capillary wedge pressure.
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two-year data (March 2013 to February 2015). Our institute has 
a computerized transfusion reaction reporting system integrated 
with the EMR. Whenever a patient is transfused, the concerned 
nurse is required to feed details about the ATRs in this system, 
irrespective of whether this information is mentioned in the 
nursing records. In case no ATR has occurred, the nurse is re-
quired to feed “no reaction” in the system. If one or more ATRs 
have occurred, the same are to be indicated in the electronic 
nursing records. In case of transfusion of red blood cells 
(RBCs), pre- and post-storage leukoreduced red blood cells 
(LR-RBCs), and single donor platelets (SDPs), a transfusion re-
port is recorded for each blood unit transfused. Thus, the trans-
fusion of one blood unit is regarded as one transfusion episode. 
In case of transfusion of whole blood-derived platelets (random 
donor platelets, RDPs), pooled leukoreduced platelets (LR-
PLTs), fresh frozen plasmas (FFPs), and cryoprecipitates, the 
transfusion of six blood units is considered as one transfusion 
episode for calculating the incidence of ATRs.
Different types of ATRs were defined in accordance with the 
criteria by the American Association of Blood Banks (AABB) [6] 
and in the hemovigilance module surveillance protocol c.2.1.3 
of the biovigilance component of the National Healthcare Safety 
Network of Centers for Disease Control and Prevention (CDC) [7] 
(Table 1). In our criteria, an acute hemolytic transfusion reaction 
(AHTR) was excluded because no AHTRs were reported due to 
our strict cross-matching and blood management system.
For this study, we initially collected data from the EMR on 
whether ATRs occurred. We also measured the proportion of 
ATRs reported in the nursing records. In case of ATRs, we col-
lected information on the type of blood components transfused 
and the reported symptoms. Blood bank physicians confirmed 
and classified these cases of ATRs [8] (Fig. 1). Finally, these 
data were further analyzed according to the types of blood com-
ponents transfused.
2. Data collection
During the two years of the study, 364,569 units of blood were 
transfused. Of them, 334,582 (91.8%) records were identified 
in the nursing records. Transfusions were categorized as either 
ATR or no reaction. We summarized the reporting rate accord-
ing to the blood components (Table 2). The 8.2% data not re-
ported in the nursing records involved transfusion in outpatients 
or in patients with transfusion during operation.
3. Statistical analysis
The frequencies of various symptoms and ATRs were calculated 
by dividing the number of cases associated with these symp-
toms and ATRs by the total number of transfusion episodes. 
The SPSS software (Version 18.0, Armonk, NY, USA) was used 
for statistical analysis. Statistical analyses involved the chi-
square test and Fisher’s exact test. P values below 0.05 were 
considered statistically significant.
RESULTS
1. Pattern of clinical signs and symptoms
The frequency of all possible transfusion-related events by nurs-
ing records was 3.1%. Fever (≥1°C increase) and chills/rigors 
were present in 53.1% and 10.6% of the symptomatic cases, re-
Fig. 1. Electronic audit system for monitoring adverse transfusion 
reactions.
Transfusion
Send the data automatically
Final confirmation of ATRs
Review by blood bank physicians
(N=334,582)
Input adverse transfusion reactions (ATRs) or no reaction 
in electronic nursing records
(N=364,569)
Table 2. Total transfusion units during March 2013 through Febru-








RBC 57,381 49,049 85.5
LR-RBC 34,634 32,397 93.5
RDP 63,967 62,209 97.3
LR-pooled PLT 141,946 139,589 98.3
SDP 8,394 8,357 99.6
FFP 55,351 40,199 72.6
Cryoprecipitate 2,896 2,782 96.1
Total 364,569 334,582 91.8
Abbreviations: RBC, red blood cell; LR-RBC, pre- and post-storage leukore-
duced red blood cell; RDP, random donor platelet; LR-pooled PLT, leukore-
duced pooled platelet; SDP, single donor platelet; FFP, fresh frozen plasma.
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spectively. The incidence of clinical signs and symptoms related 
to allergic reactions (urticaria, rash, and pruritus) in symptomatic 
cases was 16.7%. The incidence of headache, dizziness, nau-
sea/vomiting, increased blood pressure (BP), decreased BP, 
dyspnea, chest discomfort, and other signs and symptoms 
among the symptomatic cases were 1.1%, 0.6%, 1.4%, 4.5%, 
2.4%, 1.1%, 2.6%, and 5.9%, respectively (Table 3).
2. Classification of ATRs by the blood bank physicians
After the blood bank physicians’ review, the frequency of all 
possible transfusion-related events was found to be 1.2%, be-
cause 60.7% (2,467/4,062 cases) of the signs and symptoms 
identified as possible reactions turned out to be unrelated to 
transfusions after scrutiny of the cases. For instance, some 
cases were not considered FNHTRs as an increase in body 
temperature (BT) was less than 1°C or the final BT did not 
reach 38.0°C, or there were underlying conditions such as in-
fection and neutropenia that were actually responsible for the 
occurrence of fever. The number of cases classified as FNHTRs 
and allergic reactions were 895 (22.0%) and 690 (17.0%), re-
spectively (Table 4). A few cases were classified as serious 
ATRs: three cases of rule out (r/o) TAD, one case of r/o transfu-
sion-associated circulatory overload (TACO), three cases of r/o 
TRALI, and three cases of hypotensive transfusion reaction 
(HTR). Excluding the cases classified as “no reaction,” the inci-
dence of FNHTRs and allergic reactions in the remaining symp-
tomatic cases were 56.5% and 43.5%, respectively.
3.  Frequency of ATRs according to the type of blood 
components
The frequency of ATRs was compared according to the types of 
blood components transfused (RBCs, LR-RBCs, RDPs, LR-
PLTs, SDPs, FFPs, and cryoprecipitates). The frequency of 
FNHTRs was 1.2%, 0.5%, 0.4%, 0.3%, 0.2%, 0.2%, and 
0.0%, respectively, whereas that of allergic reactions was 0.3%, 
0.3%, 1.1%, 0.9%, 1.0%, 0.9%, and 0.0%, respectively (Table 
5). The frequency of FNHTRs to RBC components (RBC and 
LR-RBC; 0.9%) was significantly higher than those to FFPs 
(P <0.01) and platelet components (RDP, LR-PLT, and SDP; 





Fever (≥1°C) 2,339 53.1
Urticaria 494 11.2
Chills/Rigors 468 10.6
Increased Blood Pressure 199 4.5
Pruritus 179 4.1
Chest discomfort 113 2.6








Table 4. Adverse transfusion reactions confirmed by the blood 
bank physicians’ review
Categories 
Adverse transfusion reaction 
Number %
Febrile non-hemolytic transfusion reaction 895 22.0
Allergic reaction 690 17.0
R/O transfusion-associated dyspnea 3 0.1
R/O transfusion-related acute lung injury 3 0.1
Hypotensive transfusion reaction 3 0.1
R/O transfusion-associated circulatory overload 1 0.0
No reaction 2,467 60.7
Total 4,062 100.0
Abbreviation: R/O, rule out.
Table 5. Incidence of adverse transfusion reactions according to 















RBC 49,049 596 1.2 126 0.3 
LR-RBC 32,397 163 0.5 107 0.3 
RDP* 10,369 44 0.4 112 1.1 
LR-pooled PLT* 23,265 61 0.3 201 0.9 
SDP 8,357 15 0.2 82 1.0 
FFP* 6,700 16 0.2 62 0.9 
Cryoprecipitate* 464 0 0.0 0 0.0 
Total 130,601 895 0.7 690 0.5 
*Transfusion of six units is counted as one transfusion episode for calculat-
ing the incidence of ATRs. 
Abbreviations: FNHTR, febrile non-hemolytic transfusion reaction; RBC, red 
blood cell; LR-RBC, leukoreduced red blood cell; RDP, random donor plate-
let; LR-pooled PLT, leukoreduced pooled platelet; SDP, single donor platelet; 
FFP, fresh frozen plasma.
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P <0.01). Further, the frequency of FNHTRs to platelet compo-
nents (0.3%) was significantly higher than that to FFPs (0.2%; 
P <0.01). In contrast, the frequency of allergic reactions to 
platelet components (0.9%) and FFPs (0.9%) was significantly 
higher than that to RBC components (0.3%; P <0.01); however, 
there was no statistically significant difference between the fre-
quencies of allergic reactions to platelet components and FFPs.
We analyzed the effect of leukocyte-reduction of blood com-
ponents on the frequency of ATRs. The frequency of FNHTRs 
to RBC components was significantly lowered by leukocyte-re-
duction (0.5% to LR-RBCs vs. 1.2% to RBCs; P <0.01); how-
ever, the frequency of allergic reactions was not lowered (0.3% 
to LR-RBCs vs. 0.3% to RBCs). Similar results were obtained 
with reference to platelet components. The frequency of 
FNHTRs to LR-PLTs were significantly lower than that to RDPs 
(0.3% to LR-PLTs vs. 0.4% to RDPs; P≒0.01); however, the 
frequency of allergic reactions was not lowered by leukocyte-re-
duction (0.9% to LR-PLTs vs. 1.1% to RDPs). We also studied 
the frequency of ATRs to SDPs. The frequencies of FNHTRs to 
SDPs were significantly lower than that to RDPs (P <0.01), but 
were not significantly lower than that to LR-PLTs. Further, the 
frequency of allergic reactions to SDPs did not significantly differ 
from those to the other platelet components (Table 5).
DISCUSSION
In our hospital, from March 2013 to February 2015, 91.8% of 
the units of blood components transfused were documented by 
nurses in the nursing records using a computerized transfusion 
reaction reporting system integrated with the EMR. In this study, 
the frequency of all possible transfusion-related events was 
3.1% as per nursing records. However, after the blood bank 
physicians’ review, this frequency was found to be 1.2%. The 
reported incidence of ATRs in the literature varied widely from 
0.5% to 3% of all transfusion episodes [5]. In our study, the fre-
quency of fever, chills/rigors, and allergic reactions in the symp-
tomatic cases were 53.1%, 10.6%, and 16.7%, respectively 
(Table 3). However, the frequency of FNHTRs, allergic reac-
tions, and “no reactions” determined by transfusion physicians 
among the symptomatic cases were 22.0%, 17.0%, and 
60.7%, respectively (Table 4). The discrepancy between the re-
ported incidence by nurses and physicians was possibly be-
cause of the nurses’ use of non-standardized criteria for defin-
ing various ATRs and overlooking the underlying disease condi-
tions in the recipients. Markedly, three out of five reported clini-
cal signs and symptoms did not meet the AABB [6] and CDC 
criteria [7]. Therefore, an adequate hemovigilance system 
needs to be established at the institutional, national, and inter-
national levels [9].
According to types of blood components, the frequency of 
FNHTRs to RBC components was significantly higher than 
those to FFPs and platelet components. In contrast, the fre-
quency of allergic reactions to FFPs and platelet components 
was significantly higher than that to RBC components (Table 5).
The previously reported incidence of FNHTRs to transfused 
RBC components ranged 0.25-0.5% [3, 10-12]. In our study, it 
was 0.9%, a little higher than that reported in other studies. One 
possibility responsible for our higher rate may be that antipyretic 
premedications such as acetaminophen or diphenhydramine 
are not used in our hospital. Although recent studies found that 
premedication did not reduce the incidence of FNHTRs [5], 
higher rates of fever and chills/rigors in our study may be attrib-
uted to the lack of premedication. Another possibility may be 
the less use of LR-RBCs in our setting compared with similar 
settings in other countries [13]. The previously reported inci-
dence of FNHTRs to transfused platelets ranged 0.22-0.33% [3, 
14, 15]. Similarly, the reported rate of 0.3% in our study falls 
within this range.
In case of allergic reactions, the previously reported incidence 
to transfused RBC components ranged 0.04-0.47% [3, 10-12]. 
The reported rate of 0.3% in our study falls within this range. 
The previously reported rates of allergic reactions to transfused 
platelets ranged 0.09-2.82% [3, 14, 15]. Again, the reported 
rate of 0.9% in our study falls within this range.
It is known that FNHTRs are the most common ATRs, which 
occur owing to the cytokines released from leukocytes during 
storage and the antigen-antibody reactions in leukocytes. This 
has led to a hypothesis that incidence of FNHTRs can be de-
creased through leukocyte reduction [1, 16]. Many studies have 
been performed to verify this hypothesis. In line with various 
studies [10-12, 14], we found that the use of LR-RBCs, LR-
PLTs, and SDPs could decrease incidence of FNHTRs. How-
ever, in line with previous studies [10-12, 14], as allergic reac-
tions occur owing to antibodies against donor plasma proteins 
[6, 7], the incidence of these reactions could not be significantly 
reduced by leukocyte reduction in RBCs and PLTs.
There were one case of suspected TACO and three cases of 
suspected TRALI. All patients immediately recovered with medi-
cation and short ventilation support. In Korea, TRALI cases are 
very rare because the country’s population is ethnically homog-
enous and FFP from female donors has not been used for 
transfusion since 2009.
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There are some limitations in this study. First, some of the 
transfusion records (approximately 8.2%) were not recorded by 
nurses. This reporting gap between the nurses and physicians 
could be addressed by framing more accurate input criteria with 
regard to ATRs. Besides, continuous education should be pro-
vided to nurses with special focus on monitoring cases of TACO 
and TRALI. Second, because our online transfusion reaction re-
porting system relied on the information from concerned nurses, 
an underreporting of delayed ATRs could occur. Although these 
delayed ATRs (such as delayed hemolytic transfusion reaction, 
delayed serologic transfusion reaction, transfusion-associated 
graft-versus-host disease, or post-transfusion purpura) are rare 
and difficult to identify, comprehensive education should be 
provided to nurses for identifying and reporting symptoms pos-
sibly related to delayed ATRs [8].
We conducted a two-year retrospective study in a tertiary care 
hospital setting. We found that majority of the ATRs reported in 
this study were not serious. More significantly, we analyzed 
ATRs according to clinical correlates and blood components. 
Blood transfusion is a life-saving therapy; however, it also carries 
risks. Therefore, we need to closely monitor all transfusion epi-
sodes. By using the results of this study, prompt and effective 
provisions for preventing ATRs can be developed.
Before the implementation of the automatic reporting system, 
a few severe cases which require further problem-solving by 
blood bank physicians were reported. After the introduction of 
this system, we could count the overall transfusion reactions 
which developed in our hospital from mild to severe cases, and 
we could give good services with information of transfusion re-
actions to physicians and patients under the quality improve-
ment of transfusion.
In conclusion, this type of reporting system may improve the 
estimation of incidences of ATRs, facilitate the accurate identifi-
cation of underlying problems and risks, and contribute to qual-
ity transfusion care for patients.
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